Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. more
Time Frame | IKNA | Sector | S&P500 |
---|---|---|---|
1-Week Return | - | -1.8% | -0.77% |
1-Month Return | -2.86% | -3.48% | 0.71% |
3-Month Return | -0.58% | -7.2% | 8.81% |
6-Month Return | -6.08% | -1.54% | 12.32% |
1-Year Return | -10.99% | 8.39% | 30.57% |
3-Year Return | -88.04% | 6.07% | 29.21% |
5-Year Return | -94.69% | 44.07% | 91.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 13.75M | 9.19M | 30.98M | 15.62M | 9.16M | [{"date":"2019-12-31","value":44.39,"profit":true},{"date":"2020-12-31","value":29.67,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":50.41,"profit":true},{"date":"2023-12-31","value":29.56,"profit":true}] |
Cost of Revenue | 24.94M | 44.85M | 47.11M | 2.03M | 1.02M | [{"date":"2019-12-31","value":52.94,"profit":true},{"date":"2020-12-31","value":95.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.32,"profit":true},{"date":"2023-12-31","value":2.17,"profit":true}] |
Gross Profit | (11.19M) | (35.65M) | (16.12M) | 13.58M | 8.14M | [{"date":"2019-12-31","value":-82.34,"profit":false},{"date":"2020-12-31","value":-262.46,"profit":false},{"date":"2021-12-31","value":-118.69,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.92,"profit":true}] |
Gross Margin | (81.33%) | (387.79%) | (52.03%) | 86.98% | 88.86% | [{"date":"2019-12-31","value":-91.52,"profit":false},{"date":"2020-12-31","value":-436.38,"profit":false},{"date":"2021-12-31","value":-58.56,"profit":false},{"date":"2022-12-31","value":97.88,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 32.24M | 53.71M | 65.12M | 86.52M | 84.58M | [{"date":"2019-12-31","value":37.27,"profit":true},{"date":"2020-12-31","value":62.08,"profit":true},{"date":"2021-12-31","value":75.27,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.75,"profit":true}] |
Operating Income | (18.49M) | (44.52M) | (34.14M) | (70.90M) | (75.42M) | [{"date":"2019-12-31","value":-1849200000,"profit":false},{"date":"2020-12-31","value":-4451900000,"profit":false},{"date":"2021-12-31","value":-3413800000,"profit":false},{"date":"2022-12-31","value":-7090400000,"profit":false},{"date":"2023-12-31","value":-7541700000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | 46.00K | 4.29M | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":1.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (16.82M) | (44.26M) | (34.12M) | (68.77M) | (68.33M) | [{"date":"2019-12-31","value":-1681700000,"profit":false},{"date":"2020-12-31","value":-4425600000,"profit":false},{"date":"2021-12-31","value":-3411500000,"profit":false},{"date":"2022-12-31","value":-6876500000,"profit":false},{"date":"2023-12-31","value":-6832800000,"profit":false}] |
Income Taxes | (1.68M) | 93.70K | 307.44K | (2.14M) | (162.00K) | [{"date":"2019-12-31","value":-544.82,"profit":false},{"date":"2020-12-31","value":30.48,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-695.74,"profit":false},{"date":"2023-12-31","value":-52.69,"profit":false}] |
Income After Taxes | - | - | (34.42M) | (66.63M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-3442244200,"profit":false},{"date":"2022-12-31","value":-6662600000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (16.82M) | (44.26M) | (34.12M) | (68.75M) | (62.77M) | [{"date":"2019-12-31","value":-1681700000,"profit":false},{"date":"2020-12-31","value":-4425600000,"profit":false},{"date":"2021-12-31","value":-3411500000,"profit":false},{"date":"2022-12-31","value":-6875500000,"profit":false},{"date":"2023-12-31","value":-6277400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (16.82M) | (44.26M) | (34.12M) | (66.63M) | (68.17M) | [{"date":"2019-12-31","value":-1681700000,"profit":false},{"date":"2020-12-31","value":-4425600000,"profit":false},{"date":"2021-12-31","value":-3411500000,"profit":false},{"date":"2022-12-31","value":-6662600000,"profit":false},{"date":"2023-12-31","value":-6816600000,"profit":false}] |
EPS (Diluted) | - | (1.60) | (3.20) | (1.92) | (1.70) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-159.83,"profit":false},{"date":"2021-12-31","value":-320,"profit":false},{"date":"2022-12-31","value":-192,"profit":false},{"date":"2023-12-31","value":-170,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IKNA | |
---|---|
Cash Ratio | 14.94 |
Current Ratio | 15.32 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IKNA | |
---|---|
ROA (LTM) | -22.06% |
ROE (LTM) | -37.09% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IKNA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IKNA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 124.49 |
P/B | 0.61 |
Price/FCF | NM |
EV/R | 0.93 |
EV/Ebitda | NM |
Ikena Oncology Inc (IKNA) share price today is $1.7
Yes, Indians can buy shares of Ikena Oncology Inc (IKNA) on Vested. To buy Ikena Oncology Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IKNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ikena Oncology Inc (IKNA) via the Vested app. You can start investing in Ikena Oncology Inc (IKNA) with a minimum investment of $1.
You can invest in shares of Ikena Oncology Inc (IKNA) via Vested in three simple steps:
The 52-week high price of Ikena Oncology Inc (IKNA) is $2.32. The 52-week low price of Ikena Oncology Inc (IKNA) is $1.22.
The price-to-earnings (P/E) ratio of Ikena Oncology Inc (IKNA) is
The price-to-book (P/B) ratio of Ikena Oncology Inc (IKNA) is 0.61
The dividend yield of Ikena Oncology Inc (IKNA) is 0.00%
The market capitalization of Ikena Oncology Inc (IKNA) is $82.04M
The stock symbol (or ticker) of Ikena Oncology Inc is IKNA